<DOC>
	<DOC>NCT01461499</DOC>
	<brief_summary>The purpose of this study is to compare the effects of a direct renin inhibitor (DRI), aliskiren, on the urinary albumin excretion in hypertensive patients with type 2 diabetes under strict blood pressure control with angiotensin receptor blocker (ARB).</brief_summary>
	<brief_title>Shiga Microalbuminuria Reduction Trial-2</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Segment: outpatients Hypertension: taking an antihypertensive treatment or indicating mean sitting SBP/DBP more than130/80 mmHg Type 2 diabetes: diagnosed by ADA criteria or under an antidiabetic drug treatment Microalbuminuria: 10 &lt; and &lt; 300 mg/gCr Informed consent: patients who understand well about this study based on own voluntary will and can give a written consent Sever hypertension (over 180/110 mmHg), malignant hypertension and secondary hypertension Type 1 diabetes Patients whose investigator regards as difficult to comply with study protocol in reference to the package insert of aliskiren Patients who have history of operation in gastrointestinal tract surgery, and anamnestic or concurrent gastrointestinal disorders, which may interfere with drug absorption Serum potassium &gt; 5.6 mEq/L (hyperkalemia) Urinary microalbmiurin &lt; 10 or &gt; 300 mg/gCr Patients who participated in another clinical study within three months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Direct renin inhibitor</keyword>
	<keyword>Angiotensin receptor blocker</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>